aspirin + clopidogrel + ticagrelor + warfarin + dabigatran

This antithrombotic regimen refers to the various combinations of antiplatelet and anticoagulant therapies evaluated in the OATH-AMI clinical trial (NCT04943380). Developed and sponsored by The First Affiliated Hospital with Nanjing Medical University, the study investigates the optimal triple antithrombotic therapy (TAT) for patients with acute myocardial infarction (AMI) complicated by left ventricular mural thrombus (LVMT). The regimen involves combinations of aspirin, a P2Y12 inhibitor (either clopidogrel or ticagrelor), and an anticoagulant (either the vitamin K antagonist warfarin or the direct oral anticoagulant dabigatran). The primary therapeutic goal is to facilitate the resolution of the mural thrombus and prevent systemic embolic events, such as stroke, while maintaining an acceptable safety profile regarding major bleeding. The trial specifically explores optimized dosing, such as low-dose ticagrelor (60mg bid) and dabigatran (110mg bid), in the context of triple therapy.

Other names

antiplatelet drugs + anticoagulants-The First Affiliated Hospital with Nanjing Medical University-acute myocardial infarction-left ventricular mural thrombusOptimized Antithrombotic Therapy for AMI with LV Mural ThrombusOATH-AMI regimen